Practical resources for pharmaceutical distributors and 3PLs navigating state licensing requirements, DSCSA obligations, and regulatory compliance.
State Licensing Guides cover the application process, fees, bonding requirements, designated representative qualifications, and renewal timelines for each state's board of pharmacy.
DSCSA Compliance Guides explain Drug Supply Chain Security Act requirements including transaction documentation, verification obligations, and the 2026 enhanced serialization deadline.
Third-party logistics providers handling pharmaceutical products require separate state licenses distinct from wholesale distributor licensing. This guide covers DSCSA Section 584 requirements, state-by-state licensing, cold chain compliance, and NABP accreditation for 3PLs.
+44 more — switch to the State Licensing tab to see all.
Small dispensers have nine months to achieve full DSCSA enhanced drug distribution security compliance by November 27, 2026. This guide covers who qualifies as a small dispenser, what's exempted versus already required, technology requirements, a month-by-month preparation timeline, cost estimates, and enforcement penalties.
Complete DSCSA compliance checklist for wholesale drug distributors covering ATP verification, transaction data exchange, product identifier verification, suspect product handling, and interoperable electronic systems. All requirements are now fully enforced following the August 27, 2025 expiration of the stabilization period.
Wholesale drug distributors must verify Authorized Trading Partner (ATP) status under DSCSA before transacting with manufacturers, other distributors, and dispensers. This guide covers ATP verification methods, documentation requirements, and compliance steps for wholesale distributors subject to full DSCSA enforcement as of August 27, 2025.
DSCSA requires wholesale distributors to identify, quarantine, investigate, and report suspect and illegitimate products under Section 582(c)(4). FDA enforcement began August 27, 2025, with 24-hour notification requirements for illegitimate product determinations and mandatory package-level verification during investigations.
+2 more — switch to the DSCSA tab to see all.
NABP Drug Distributor Accreditation (formerly VAWD) is a three-year voluntary program verifying wholesale pharmaceutical distributor compliance. Only 755 of ~1,951 US distributors hold accreditation — 4 states mandate it, and major healthcare entities now require it contractually. Cost: $12,500 per three-year cycle.
Learn the 5-step process to verify wholesale drug distributor licenses across state boards, FDA, NABP, DEA, and DSCSA databases. Includes red flags, real enforcement cases, and how ColdChainCheck consolidates verification into a single compliance score.
ColdChainCheck tracks 1,275 wholesale pharmaceutical distributors across 51 US jurisdictions. This guide covers distributor types, federal and state licensing requirements, DSCSA compliance obligations, and verification workflows using publicly available data.
72% of wholesale drug distributors cluster in the Fair compliance tier (40-59 points), with a median score of 52/100. NABP accreditation remains the industry's largest gap: only 4.9% of 1,275 tracked entities hold VAWD or DSCSA Ready status, losing an average 23.8 points on this component alone.
Guides are reviewed periodically but regulatory requirements change. Always verify directly with state boards and federal agencies before making compliance decisions.